Stocks and Investing Stocks and Investing
Fri, October 27, 2017

Stephen Willey Maintained (BMRN) at Strong Buy with Decreased Target to $105 on, Oct 27th, 2017


Published on 2024-10-26 00:08:33 - WOPRAI, Stephen Willey
  Print publication without navigation


Stephen Willey of Stifel, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $107 to $105 on, Oct 27th, 2017.

Stephen has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 2 agree with Stephen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017


These are the ratings of the 5 analyists that currently disagree with Stephen


  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $124 on, Thursday, October 19th, 2017
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $142 on, Thursday, October 19th, 2017
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017

Contributing Sources